Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study

Recruiting now

Conditions studied: Follicular Lymphoma

In brief

This study is planned to prospectively observe and verify the efficacy and safety of induction therapy with obinutuzumab in combination with lenalidomide followed by maintenance therapy with obinutuzumab and lenalidomide in patients with R/R FL in a real-world setting in a Chinese population.

Key facts

Study ID

NCT05846763

Run by

Institute of Hematology & Blood Diseases Hospital, China

People needed

50

Starts

2022-11-01

Expected to finish

2028-05-31

Last updated by the study team

2023-05-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Patients currently participating or planning to participate in any interventional clinical trial
• Any other reason that, in the opinion of the investigator, makes the patient unsuitable for this study

Where it is running

• Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences — Tianjin, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.